Evidence map›Paper›PMID 33902199›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021

[New insights into immunotolerant phase of chronic hepatitis B virus infection].

M H Duan, X E Liu, H Zhuang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. [Let's start from practical for returning academics to the clinic].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  2. [HBV infection: antiviral therapy for viral replication].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

M H DuanDepartment of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
X E LiuDepartment of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
H ZhuangDepartment of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.

Funding

Major Science and Technology Special Project of China Thirteenth Five-year Plan 2018ZX10732401-003-015
6 · The paper itself

Abstract

Patients in "immunotolerant phase" of chronic hepatitis B virus infection are HBsAg and HBeAg-positive, with high HBV DNA level, normal ALT and no obvious histopathological hepatic necrotizing inflammation or fibrosis. However, in recent years, some studies have found that HBV DNA integration, clonal hepatocyte expansion, HBV-specific T cell immune response, liver injury and disease progression exist in patients with "immunotolerant phase" of chronic HBV infection. Therefore, the concept of "immunotolerant phase" is controversial. This paper summarizes the new insights into the "immunotolerant phase" of chronic hepatitis B virus infection, including its new concepts in nomenclature, diagnosis, treatment and management.

Indexed as

Hepatitis B, ChronicLiver NeoplasmsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansImmune ToleranceDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensChronic hepatitis BHepatitis B virusHepatocellular carcinomaImmune toleranceLiver fibrosis

Identifiers

PMID33902199
PMCPMC12814754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.